In their recent half yearly report, management offered 2024 FY EBITDA guidance between $1.7b and $1.8b and then further qualified that prediction by stating that the profit would be "more likely towards lower end of guidance range".
When I build a result using $1.7b as the EBITDA for the 2024 financial year I worked up a Profit before Tax of $886m and, after applying a tax rate of 27%, again from their half yearly report, I suspect that EPS may settle around $1.30 to $1.35 for the current financial year.
A share price of $26.50 suggests a P/E ratio of about 19 to 20 which is the maximum I would pay for this business.
Much of their growth comes through acquisition funded by external debt, and, because these acquisitions occur regularly, it's hard to determine the real organic growth rate of the business, but I've come up with estimates over time of about 5 to 6% (EPS in 2019 was $1.22 so $1.35 in 2024 is not startling - ROE across the last 10 years has stuck around 10% with the exception of the Covid years of course).
I bought back in today but only in a small way as I'm not convinced that they'll achieve their stated profit guidance for 2024.
We'll see.
- Forums
- ASX - By Stock
- Ann: Half Yearly Report and Accounts
In their recent half yearly report, management offered 2024 FY...
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SHL (ASX) to my watchlist
(20min delay)
|
|||||
Last
$26.28 |
Change
0.160(0.61%) |
Mkt cap ! $12.62B |
Open | High | Low | Value | Volume |
$26.12 | $26.37 | $26.06 | $19.10M | 727.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 100 | $26.27 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$26.40 | 200 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100 | 26.270 |
3 | 5152 | 26.260 |
2 | 600 | 26.250 |
2 | 11883 | 26.240 |
1 | 1833 | 26.230 |
Price($) | Vol. | No. |
---|---|---|
26.400 | 200 | 1 |
26.410 | 3652 | 2 |
26.430 | 4517 | 3 |
26.450 | 5652 | 2 |
26.470 | 3652 | 1 |
Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
Last
$26.33 |
  |
Change
0.160 ( 0.87 %) |
|||
Open | High | Low | Volume | ||
$26.14 | $26.37 | $26.06 | 599086 | ||
Last updated 15.59pm 06/05/2024 ? |
Featured News
SHL (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online